Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers impede impulse transmission through multiple mechanisms. They can induce persistent depolarization of postsynaptic neurons, block acetylcholine release, or act as competitive antagonists by binding to nicotinic receptors. Some function as noncompetitive blockers, obstructing ion channels essential for neurotransmission. These diverse mechanisms collectively suppress autonomic activity at both sympathetic and parasympathetic ganglia.

Ganglionic blockers fall into two primary categories. Prototype nicotine agents stimulate ganglia through acetylcholine-like action, causing consistent depolarization and subsequent blockade. Competitive antagonists like trimethaphan and mecamylamine compete with acetylcholine for nicotinic receptor binding, preventing impulse transmission. Mecamylamine uniquely crosses the blood-brain barrier, distinguishing it from other competitive antagonists.

Sympathetic ganglia blockade causes significant arterial vasodilation and reduces blood pressure through blockage of cardiovascular reflexes. This leads to postural hypotension, a sudden decrease in arterial pressure causing fainting when changing positions. Ganglionic blockers also induce postexercise hypotension and inhibit vasoconstriction of dilated arteries, while cerebral blood flow reduction remains minimal.

Parasympathetic ganglia blockade produces diverse adverse effects including abdominal discomfort, nausea, dry mouth, syncope, urinary retention, and cycloplegia. These effects reflect suppressed parasympathetic activity throughout the body. Additionally, ganglionic blockers cause constipation and prolonged neuromuscular blockade, contributing to their limited clinical use despite effectiveness in managing hypertensive emergencies.

Most ganglionic blockers are ionized compounds, meaning they carry electrical charges that restrict their ability to cross cell membranes. This ionization limits their permeability and affects their pharmacokinetic properties. However, mecamylamine is an exception, as its structure allows it to cross the blood-brain barrier, distinguishing it pharmacologically from other ganglionic blocking agents.

Ganglionic blockers are rarely used clinically today due to erratic absorption, incomplete effects, and significant adverse effects. No agents are currently commercially marketed. However, they remain valuable in experimental pharmacology as research tools. Historically, they managed hypertensive emergencies and aided smoking cessation, but safer alternatives have largely replaced them in therapeutic applications.

Ganglionic blockers specifically target nicotinic receptors in autonomic ganglia and lack selectivity between sympathetic and parasympathetic divisions. They are ineffective as neuromuscular junction antagonists because they cannot adequately access or block receptors at the neuromuscular junction. This distinction makes ganglionic blockers selective for autonomic ganglia while sparing skeletal muscle function.